CEO Message

“Once again, with Creation and Innovation”

We extend our deepest gratitude to all stakeholders who support Hanmi Pharmaceutical.

Last year, Hanmi Pharmaceutical achieved a record-high revenue of KRW 1.5475 trillion since its founding, and recorded an industry-leading operating profit of KRW 257.8 billion. The company has gone beyond mere external growth, establishing a more robust growth foundation based on solid fundamentals, where top-tier profit generation and R&D investment create a virtuous cycle.

In the new drug development sector, which will drive Hanmi Pharmaceutical's future value, visible achievements are being made.
The obesity new drug slated for launch in the second half of this year is expected to leap forward as a 'national obesity drug' based on its excellent efficacy and confirmed safety, and
in the fields of oncology, metabolic diseases, and rare diseases, we are preparing to announce encouraging clinical results.

Hanmi Pharmaceutical will further strengthen its professional management system and organically consolidate group-level capabilities to promote enhanced corporate value and sustainable growth.

We deeply thank all stakeholders for their unreserved trust and support, and
we kindly ask for your continued interest and encouragement as Hanmi Pharmaceutical establishes itself as a leading company in the Korean pharmaceutical industry.

Thank you.

April 2026

Hwang Sangyoun, CEO